Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 150 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Veno-occlusive Disease Clear all
Completed Not applicable Interventional Results available

Using Ultrasound Elastography to Predict Development of SOS

NCT02483481
View directory record Official record
Conditions
Sinusoidal Obstruction Syndrome, Complications of Bone Marrow Transplant
Interventions
shear wave ultrasound elastography
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Jul 21, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional Results available

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

NCT00770770
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

NCT00168324
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
700 µg Dexamethasone, 350 µg Dexamethasone, Sham Injection
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jul 21, 2026, 6:45 AM EDT
Active, not recruiting Not applicable Interventional Results available

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

NCT05409976
View directory record Official record
Conditions
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions
GORE® VIAFORT Vascular Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
8
States / cities
Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Recruiting Not applicable Interventional

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

NCT05489588
View directory record Official record
Conditions
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions
GORE® VIAFORT Vascular Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
27
States / cities
Stanford, California • Thornton, Colorado • Darien, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

NCT01428388
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose)
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

VIRTUS: An Evaluation of the Vici™ Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow Obstruction

NCT02112877
View directory record Official record
Conditions
Chronic Venous Disorder, Venous Outflow Obstruction, Symptomatic Venous Outflow Obstruction of Iliofemoral Vein
Interventions
Veniti Vici™ Venous Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
16
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Jul 21, 2026, 6:45 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

NCT01011374
View directory record Official record
Conditions
Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
Interventions
ranibizumab (Lucentis)
Drug
Lead sponsor
Retina Associates of Cleveland, Inc
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Results available

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

NCT03677596
View directory record Official record
Conditions
Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma, ACUTE LYMPHOBLASTIC LEUKEMIA
Interventions
inotuzumab ozogamicin-dose level 2, Inotuzumab ozogamicin-dose level 1
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

NCT01969708
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
aflibercept, bevacizumab
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Surfacer System Approach to Central Venous Access

NCT03209050
View directory record Official record
Conditions
Venous Occlusion
Interventions
Central Venous Access Placement
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2023 · Synced Jul 21, 2026, 6:45 AM EDT
Active, not recruiting Phase 3 Interventional

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

NCT05112861
View directory record Official record
Conditions
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
bevacizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Springfield, Illinois • Hagerstown, Maryland • Chambersburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Completed No phase listed Observational

Venogram vs. Intravascular Ultrasound (IVUS) for Diagnosing Iliac Vein Obstruction

NCT02142062
View directory record Official record
Conditions
Iliac Venous Compression
Interventions
Not listed
Lead sponsor
Volcano Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bridgeport, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion

NCT00406471
View directory record Official record
Conditions
Ischemic Central Retinal Vein Occlusion
Interventions
Ranibizumab (Lucentis)
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

NCT00358501
View directory record Official record
Conditions
Severe Hepatic Veno-Occlusive Disease
Interventions
Defibrotide
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
22
States / cities
Duarte, California • Palo Alto, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

NCT01231633
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion
Interventions
Ozurdex, Avastin
Drug
Lead sponsor
Long Island Vitreoretinal Consultants
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Toms River, New Jersey • Great Neck, New York • Hauppauge, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients

NCT02851407
View directory record Official record
Conditions
Veno-occlusive Disease
Interventions
Defibrotide, Best Supportive Care
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Results available

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

NCT03727750
View directory record Official record
Conditions
ECG, Pharmacokinetics, Safety
Interventions
Gemtuzumab Ozogamicin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Augusta, Georgia • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jul 21, 2026, 6:45 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)

NCT00211354
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Anecortave Acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

NCT01085734
View directory record Official record
Conditions
Retinal Vein Occlusions
Interventions
Avastin, Osurdex
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 2 Interventional

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Jul 21, 2026, 6:45 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Study Evaluating Retinal Health Monitoring System Thickness Module

NCT04428242
View directory record Official record
Conditions
Macular Edema, Macular Degeneration
Interventions
RHMS-RTM, SD-OCT
Device · Diagnostic Test
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 21, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

NCT07205887
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Interventions
EYE103, Aflibercept 2.0 mg
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
49
States / cities
Scottsdale, Arizona • Glendale, California • Modesto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
pegaptanib sodium (Macugen)
Drug
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Jul 21, 2026, 6:45 AM EDT